Objective
My PhD experience in the field of immunology focused on deciphering vesicular pathways underlying T cell activation profoundly motivated my move to Dr. Bryceson’s lab, which offers a unique opportunity to explore cytotoxic lymphocyte (CL) exocytosis in the context of human disease. Cytotoxic lymphocyte exocytosis is critical for life, with mutations in genes required for cytotoxicity causative of severe, early-onset hyperinflammatory syndromes. Genetic studies have identified several cytosolic proteins required for CL exocytosis. However, understanding of how these proteins cooperate for exocytosis, their interaction partners and how their activities are regulated is still limited. I propose strategies to gain insight to the molecular regulation of human CL exocytosis. First, prompted by genetic studies, I aim to study the contribution of two distinct Munc13-4 isoforms to lymphocyte cytotoxicity by dissecting their role in cytotoxic granule (CG) exocytosis using advanced live-cell imaging as well as identifying their interaction partners using quantitative mass spectrometry (MS). Second, recycling endosome (RE) have recently been implicated in CG exocytosis, delivering syntaxin-11, an effector molecule required for CG fusion, to the plasma membrane. I plan to use a high-throughput MS approach to identify RE constituents and cargo in order to define new components that may be critical for CG exocytosis. Results will provide novel mechanistic insights to CL exocytosis, which will also be relevant for other exocytic systems. Providing detailed molecular understanding of lymphocyte cytotoxicity in both healthy and pathological conditions, insights promise to guide improved diagnosis and therapy of immune disorders associated with defects in lymphocyte cytotoxicity. Yearning to build a successful academic career, the excellence of the host laboratory will allow me to successfully purse this project and expand technical expertise and my scientific horizon.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- natural sciences biological sciences biochemistry biomolecules proteins
- medical and health sciences basic medicine immunology
- natural sciences biological sciences genetics mutation
- natural sciences chemical sciences analytical chemistry mass spectrometry
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
MSCA-IF-EF-ST - Standard EF
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-MSCA-IF-2017
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
171 77 STOCKHOLM
Sweden
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.